Company / Current Assets
Cullinan Therapeutics, Inc. Current Assets History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$414.7M
FY2024
5-year range
$212.3M / $480.2M
FY2020-FY2024
Trend
-13.6%
vs FY2023
Sector context
#131 of 213
Health Care
What the data says
At $415M, Cullinan Therapeutics, Inc.'s current assets ranks #131 of 213 in the Health Care sector. Declined from $474M to $415M over the past 2 years.
Based on SEC 10-K filings.
$415M in FY2024 with a 3-year CAGR of +11.8%.
Declined from $474M to $415M over the past 2 years.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- +11.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#131 of 213 in Health CareTop 62% of 213This company $414.7M Sector average $2.5B
▼
-83.6% below sector average
Key checks
Key Insights
- 3-year CAGR of +11.8%, indicating consistent growth.
- In FY2024, current assets decreased 13.6% year-over-year.
- Ranks #131 out of 213 companies in the Health Care sector.
- Peak current assets was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.33 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $414.7M | -13.6% |
| FY2023 | $480.2M | +1.2% |
| FY2022 | $474.5M | +60.0% |
| FY2021 | $296.6M | +39.7% |
| FY2020 | $212.3M | - |
As of FY2024 · SEC 10-K · Updated Jul 2, 2026